Roche-backed Chugai taps into longevity field with Pfizer-allied Gero

Kyle LaHucik

Biotech Correspondent

Japanese drugmaker Chugai is wading into the aging-related disease landscape, an area of drug R&D that’s gaining more traction among pharmaceutical giants.

The Tokyo-headquartered company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Roche-backed Chugai taps into longevity field with Pfizer-allied Gero

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

Apogee reports Phase 2 win for eczema drug that could challenge Sanofi’s Dupixent and Lilly’s Ebglyss

Number of megarounds drops 38% in first half as biotechs struggle against worsening slump

Novartis' Cosentyx fails Phase 3 study for autoimmune disease

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

Roche-backed Chugai taps in­to longevi­ty field with Pfiz­er-al­lied Gero

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

De­spite de­lay, KalVista wins FDA ap­proval af­ter Makary's short-lived at­tempt to in­ter­vene

Apogee re­ports Phase 2 win for eczema drug that could chal­lenge Sanofi’s Dupix­ent and Lil­ly’s Ebglyss

Num­ber of megarounds drops 38% in first half as biotechs strug­gle against wors­en­ing slump

No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

Roche-backed Chugai taps into longevity field with Pfizer-allied Gero

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

Apogee reports Phase 2 win for eczema drug that could challenge Sanofi’s Dupixent and Lilly’s Ebglyss

Number of megarounds drops 38% in first half as biotechs struggle against worsening slump

Novartis' Cosentyx fails Phase 3 study for autoimmune disease

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases